Serum Anti-Müllerian Hormone: A Potential Biomarker for Polycystic Ovary Syndrome

    September 2023 in “ International Journal of Microbiology Research ”
    Ashutosh Halder, Hemant Kumar, Mona Sharma … Shivam Pandey
    Studysummary This study suggests that anti-Müllerian hormone (AMH) is the most promising biomarker for diagnosing polycystic ovary syndrome (PCOS), especially in women with phenotype A and D.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.lww.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Diagnostic Criteria for PCOS: Is There a Need for a Rethink? Best Practice & Research in Clinical Obstetrics & Gynaecology · 2016
    2. Androgen Profile Through Life in Women With Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study The Journal of Clinical Endocrinology and Metabolism · 2015
    3. Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS) Human Reproduction · 2003

    Related research 4

    1. Correlation of Clinical and Biochemical Hyperandrogenism in Thai Women with Polycystic Ovary Syndrome Journal of Obstetrics and Gynaecology Research · 2016
    2. Hyperandrogenism in Women: Polycystic Ovary Syndrome Hanyang Medical Reviews · 2012
    3. Diagnosis of Hyperandrogenism: Clinical Criteria Best Practice & Research Clinical Endocrinology & Metabolism · 2006
    4. Spironolactone Therapeutic Effect in the Hyperandrogenism Syndrome Problemy e̊ndokrinologii · 1993